Your browser is no longer supported. Please, upgrade your browser.
Settings
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
KALA [NASD]
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own0.90% Shs Outstand40.76M Perf Week-1.50%
Market Cap589.43M Forward P/E- EPS next Y-1.36 Insider Trans- Shs Float33.19M Perf Month-20.83%
Income-90.90M PEG- EPS next Q-0.42 Inst Own85.10% Short Float10.83% Perf Quarter18.26%
Sales5.80M P/S101.63 EPS this Y-10.60% Inst Trans70.64% Short Ratio3.34 Perf Half Y122.72%
Book/sh3.47 P/B3.02 EPS next Y24.90% ROA-48.30% Target Price- Perf Year71.97%
Cash/sh3.50 P/C3.00 EPS next 5Y- ROE-132.10% 52W Range3.24 - 14.68 Perf YTD184.28%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-87.40% 52W High-28.54% Beta-
Dividend %- Quick Ratio11.90 Sales past 5Y67.90% Gross Margin63.20% 52W Low223.77% ATR0.81
Employees136 Current Ratio12.20 Sales Q/Q-21.40% Oper. Margin- RSI (14)37.74 Volatility6.10% 7.33%
OptionableYes Debt/Eq0.00 EPS Q/Q28.10% Profit Margin- Rel Volume0.89 Prev Close10.64
ShortableYes LT Debt/Eq0.50 EarningsMay 07 BMO Payout- Avg Volume1.08M Price10.49
Recom1.30 SMA20-11.12% SMA50-12.50% SMA20046.02% Volume947,196 Change-1.41%
Jun-01-20Resumed Oppenheimer Outperform $21
May-27-20Reiterated H.C. Wainwright Buy $14 → $17
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Jun-23-20 11:01AM  
Jun-10-20 08:00AM  
Jun-05-20 11:30AM  
Jun-02-20 08:41AM  
May-28-20 08:16AM  
May-27-20 08:00AM  
May-26-20 11:41AM  
08:00AM  
May-19-20 11:30AM  
May-09-20 10:01PM  
May-07-20 10:05AM  
08:23AM  
07:00AM  
May-06-20 08:00AM  
May-05-20 12:00PM  
09:03AM  
May-04-20 08:00AM  
May-01-20 11:30AM  
Apr-30-20 08:00AM  
Apr-17-20 04:01PM  
Apr-16-20 12:00PM  
Apr-08-20 11:01AM  
10:42AM  
Apr-07-20 11:30AM  
Apr-03-20 04:01PM  
Mar-20-20 08:30PM  
Mar-15-20 04:24PM  
Mar-11-20 11:06AM  
10:50AM  
Mar-10-20 11:02PM  
04:44PM  
11:30AM  
09:31AM  
09:24AM  
Mar-09-20 06:00AM  
Mar-06-20 10:11AM  
Feb-20-20 04:01PM  
Feb-12-20 11:30AM  
08:35AM  
07:00AM  
Feb-09-20 03:22PM  
Feb-06-20 11:53AM  
08:00AM  
Feb-03-20 11:11AM  
Jan-30-20 11:10AM  
Jan-22-20 09:45AM  
09:33AM  
Jan-15-20 08:00AM  
Jan-14-20 09:21AM  
Jan-08-20 08:00AM  
Dec-19-19 09:53PM  
04:05PM  
Dec-12-19 04:11PM  
Nov-19-19 04:05PM  
Nov-07-19 08:25AM  
07:00AM  
Nov-04-19 04:30PM  
Oct-21-19 04:05PM  
Oct-11-19 08:34AM  
Sep-25-19 08:40AM  
Sep-19-19 04:05PM  
Aug-29-19 08:00AM  
Aug-27-19 08:56AM  
Aug-23-19 11:24AM  
Aug-20-19 04:05PM  
Aug-19-19 07:08AM  
Aug-08-19 04:01PM  
Aug-06-19 03:40PM  
02:23PM  
09:45AM  
07:00AM  
Jul-30-19 04:05PM  
Jul-22-19 08:02AM  
Jun-20-19 04:05PM  
Jun-13-19 03:11PM  
May-30-19 08:00AM  
May-17-19 04:05PM  
May-16-19 02:15PM  
May-09-19 08:15AM  
07:08AM  
07:00AM  
May-02-19 08:00AM  
Apr-29-19 08:59AM  
Apr-25-19 11:35AM  
Apr-18-19 04:05PM  
Apr-01-19 08:00AM  
Mar-14-19 10:24AM  
Mar-11-19 04:12PM  
04:01PM  
Mar-06-19 08:00AM  
Mar-04-19 08:00AM  
Feb-22-19 04:05PM  
Jan-18-19 04:05PM  
Jan-07-19 07:00AM  
Jan-04-19 07:52AM  
Jan-02-19 08:00AM  
Dec-28-18 07:20AM  
Dec-26-18 07:00AM  
Dec-19-18 04:05PM  
Nov-23-18 08:00AM  
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trachtenberg EricSee RemarksJun 19Option Exercise5.1928,901149,99628,901Jun 22 04:06 PM
Reumuth MaryChief Financial OfficerJun 09Option Exercise2.6443,477114,77148,293Jun 11 04:58 PM
Brazzell Romulus KChief Medical OfficerApr 09Option Exercise2.9967,771202,377176,496Apr 13 08:38 AM
Chen HongmingChief Scientific OfficerMar 30Option Exercise2.3031,00071,30086,849Apr 01 04:43 PM
Bazemore ToddChief Operating OfficerMar 16Buy5.7510,00057,50010,000Mar 17 05:46 PM
Grunberg GregoryDirectorMar 13Buy7.892,534,85419,999,9982,534,854Mar 16 07:59 AM
Shah Rajeev M.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:47 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:45 PM
Rosen Howard BDirectorAug 19Option Exercise0.604,8242,8724,824Jun 29 09:54 PM